apoe-genotyping_EURORealTime APOE
Science

EU approves Alzheimer’s drug – APOE genotype decisive for access to therapy

On 15th April 2025, the European Commission authorised lecanemab (monoclonal anti-amyloid (beta) antibody; trade name: Leqembi from Eisai and Biogen) in the European Union to treat early Alzheimer’s disease. A decision was long awaited after the positive opinion on the marketing authorisation of the medicine by the European Medicines Agency (EMA) in November 2024. The […]

Products

HAND IN HAND FOR POWERFUL ENDOCRINOLOGY – Test systems backed up by extensive scientific studies for the assessment of growth disorders, combining quality and progress

If a child grows significantly slower or is much smaller than their peers, parents generally get worried. While this may just be a temporary delay that balances out in later growth phases, a lack of growth can also have endocrine causes and may persist: Such growth disorders require treatment and stem from a lack of

IDS i20
Products

NEW! IDS i20 – ChLIA automation of the next i-generation

Reliability, versatility and usability of automation solutions are crucial in diagnostic laboratories. The random access device IDS i20 joins the IDS-i10 and IDS-iSYS in the i-series and was developed to fulfil precisely these requirements for the processing of chemiluminescence immunoassays (ChLIA). This makes it possible to maximise standards even with high sample numbers, to minimise

Endocrinology diagnostics IDS and EUROIMMUN. Hypertension Adrenal function Growth disorders Bone metabolism Reproduction
Products

HAND IN HAND FOR POWERFUL ENDOCRINOLOGY – Test systems backed up by extensive scientific studies for the assessment of bone disorders, combining quality and progress

As Mary S. (71) puts down her heavy shopping bag, she suddenly feels a sharp pain in her forearm. Her general practitioner, whom she visits the next day, immediately refers her to radiology. The x-ray confirms the suspected diagnosis of a fractured radius. But that is not all. Mary also appears to suffer from osteoporosis,

Science

EUROIMMUN Anti-Acetylcholine Receptor ELISA shows high concordance with radioimmunoassay

The EUROIMMUN Anti-Acetylcholine Receptor ELISA shows a high overall concordance with traditional radioimmunoassay (RIA) in patients with myasthenia gravis (MG), while offering advantages such as avoidance of radioisotope waste. This was the conclusion of a study on patients in Japan, which was performed as part of a collaboration between EUROIMMUN and scientists at the Neurology

Scroll to Top